[1]
|
Zheng, R.S., Zhang, S.W., Zeng, H.M., et al. (2022) Cancer Incidence and Motality in China, 2016. Journal of the Na-tional Cancer Center, 2, 1-9.
|
[2]
|
Haupt, S., Caramia, F., Klein, S.L., Rubin, J.B. and Haupt, Y. (2021) Sex Disparities Matter in Cancer Development and Therapy. Nature Reviews Cancer, 21, 393-407. https://doi.org/10.1038/s41568-021-00348-y
|
[3]
|
徐源佑, 张永辉, 丁璐璐, 等. 1972~2016年江苏省启东市膀胱癌生存率长期趋势分析[J]. 中国肿瘤, 2022, 31(9): 710-715.
|
[4]
|
Moran, G.W., Li, G., Robins, D.J., et al. (2017) Systematic Review and Meta-Analysis on the Efficacy of Chemotherapy with Transurethral Resection of Bladder Tumors as Definitive Therapy for Muscle Invasive Bladder Cancer. Bladder Cancer, 3, 245-258. https://doi.org/10.3233/BLC-170134
|
[5]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[6]
|
王丽鹃, 刘自晓, 胡伟, 等. 膀胱癌淋巴结转移术前评估研究进展[J]. 中国医学科学院学报, 2023, 45(3): 464-470.
|
[7]
|
Youssef, R.F. and Raj, G.V. (2011) Lymphadenectomy in Man-agement of Invasive Bladder Cancer. International Journal of Surgical Oncology, 2011, Article ID: 758189. https://doi.org/10.1155/2011/758189
|
[8]
|
Shariat, S.F., Ehdaie, B., Rink, M., et al. (2012) Clinical Nodal Staging Scores for Bladder Cancer: Aproposal for Preoperative Risk Assessment. European Urology, 61, 237-242. https://doi.org/10.1016/j.eururo.2011.10.011
|
[9]
|
陈双. 膀胱癌转移淋巴结最大径的预后意义及在TNM分期中的价值[D]: [硕士学位论文]. 广州: 南方医科大学, 2019.
|
[10]
|
黄翻. 膀胱癌淋巴结转移与其分期分级相关性的回顾性分析[D]: [硕士学位论文]. 昆明: 昆明医科大学, 2020.
|
[11]
|
孙其鹏, 狄金明, 湛海伦, 等. 根治性膀胱切除术前淋巴结转移预测的相关指标分析[J]. 中华腔镜泌尿外科杂志(电子版), 2014, 8(5): 334-337.
|
[12]
|
Stein, J.P., Cai, J., Groshen, S., et al. (2003) Risk Factors for Patients with Pelviclymph Node Metastases Following Radical Cystectomy with En Blocpelvic Lymphadenectomy: Concept of Lymph Node Density. Journal of Urology, 170, 35-41. https://doi.org/10.1097/01.ju.0000072422.69286.0e
|
[13]
|
申克辉, 虞巍, 张凯, 等. 不同病理分级分期膀胱癌淋巴结转移的分布状态: 208例根治性膀胱切除连续病例分析[J]. 中华泌尿外科杂志, 2010(2): 99-103.
|
[14]
|
Her-mans, T.J.N., Voskuilen, C.S., Deelen, M., et al. (2019) Superior Efficacy of Neoadjuvant Chemotherapy and Radical Cystectomy in cT3-4aN0M0 Compared to cT2N0M0 Bladder Cancer. International Journal of Cancer, 144, 1453-1459. https://doi.org/10.1002/ijc.31833
|
[15]
|
Massari, F., Santoni, M., di Nunno, V., et al. (2018) Adjuvant and Neoad-juvant Approaches for Urothelial Cancer: Updated Indications and Controversies. Cancer Treatment Reviews, 68, 80-85.
https://doi.org/10.1016/j.ctrv.2018.06.002
|
[16]
|
李慧, 姜行康, 马宝杰, 等. 淋巴血管侵犯在电切术后高级别T_1期膀胱癌中的临床病理意义[J]. 中华泌尿外科杂志, 2015, 36(2): 126-130.
|
[17]
|
Tilki, D., Shariat, S.F., Lotan, Y., et al. (2012) Lymphovascular Invasion is Independently Associated with Bladder Cancer Recurrence and Survival in Patients with Final Stage T1 Disease and Negative Lymph Nodes after Radical Cystectomy. BJU International, 111, 1215-1221. https://doi.org/10.1111/j.1464-410X.2012.11455.x
|
[18]
|
Witjes, J.A., Bruins, H.M.M., Cathomas, R.L., et al. (2020) European Association of Urology Guidelines on Muscle-Invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. European Urology, 79, 82-104.
https://doi.org/10.1016/j.eururo.2020.03.055
|
[19]
|
林明亮, 李科威, 王启开, 等. 肌层浸润性膀胱癌保留膀胱综合治疗的疗效分析[J]. 潍坊医学院学报, 2023, 45(5): 362-365.
|
[20]
|
周述银, 周健, 张茂. 长非编码RNA PCAT7对肌层浸润性膀胱癌发病的影响[J]. 南昌大学学报(医学版), 2019, 59(5): 21-23+51.
|
[21]
|
谢伟槟, 刘皓, 孔坚秋, 等. 膀胱癌盆腔淋巴结转移的规律及影响因素分析[J]. 中华腔镜泌尿外科杂志(电子版), 2018, 12(6): 397-401.
|
[22]
|
郝瀚, 吴鑫, 郑卫, 等. 膀胱尿路上皮癌淋巴结转移特点: 单中心522例膀胱根治性切除病例回顾[J]. 北京大学学报(医学版), 2014, 46(4): 524-527.
|
[23]
|
Gschwend, J.E., Heck, M.M., Lehmann, J., et al. (2016) Limited versus Extended Pelvic Lymphadenectomy in Patients with Bladder Cancer Undergoing Radical Cystectomy: Survival Results from a Prospective, Randomized Trial (LEA AUO AB 25/02). Journal of Clinical Oncology, 34, 4503-4503. https://doi.org/10.1200/JCO.2016.34.15_suppl.4503
|